Table 2 Characteristics of patients taking standard (20 mg) or reduced (15 mg) dose rivaroxaban
| Reduced Dose (15 mg daily) | Standard Dose (20 mg daily) | P-value | |
|---|---|---|---|
| Total number of patients | 6467 | 13,245 | |
| Age Category, years | < 0.001 | ||
| 65–69 | 7.9% | 18.2% | |
| 70 to 74 | 14.8% | 29.0% | |
| 75 to 79 | 20.7% | 25.6% | |
| 80 to 84 | 25.4% | 17.0% | |
| 85 to 89 | 19.8% | 7.8% | |
| 90 or over | 11.4% | 2.4% | |
| Sex | < 0.001 | ||
| Female | 57.1% | 46.2% | |
| Male | 42.9% | 53.8% | |
| Race Category | < 0.001 | ||
| White | 85.2% | 85.8% | |
| Black | 9.0% | 8.0% | |
| Hispanic | 2.2% | 1.6% | |
| Asian | 0.8% | 0.8% | |
| Other | 2.8% | 3.8% | |
| Smoking | 20.2% | 22.8% | < 0.001 |
| Alcohol | 2.3% | 3.2% | < 0.001 |
| Weight Category (based on ICD-9 and ICD-10 codes for BMI Category) | < 0.001 | ||
| Under-Weight | 2.3% | 1.3% | |
| Healthy or Overweight | 19.1% | 14.3% | |
| Obese or Severe Obese | 26.2% | 31.2% | |
| Not available | 52.4% | 53.2% | |
| Comorbid Conditions | |||
| Prior Stroke | 28.2% | 22.4% | < 0.001 |
| Prior major bleeding from Diagnosis | 26.6% | 23.9% | < 0.001 |
| Gastrointestinal bleeding | 15.2% | 13.5% | 0.002 |
| Cerebral bleeding | 1.3% | 0.8% | < 0.001 |
| Diabetes | 51.0% | 47.7% | < 0.001 |
| Prior AMI | 9.0% | 5.7% | < 0.001 |
| Liver Disease | 2.9% | 3.1% | 0.35 |
| Heart Failure | 35.6% | 24.3% | < 0.001 |
| Hypertension | 94.6% | 92.1% | < 0.001 |
| Ischemic cardiomyopathy | 47.7% | 40.2% | < 0.001 |
| Pulmonary | 15.9% | 11.1% | < 0.001 |
| COPD | 36.3% | 31.4% | < 0.001 |
| Transfusion from Procedure | 5.0% | 2.3% | < 0.001 |
| Revascularization | 16.5% | 13.7% | < 0.001 |
| Implantable Devices | 16.7% | 12.5% | < 0.001 |
| Valve Disease | 40.6% | 36.4% | 0.002 |
| Renal Disease (ICD-9 and ICD-10 codes) | < 0.001 | ||
| None or Mild (Stage I, II) | 54.8% | 83.9% | |
| Moderate (Stage III) | 37.5% | 14.5% | |
| Severe (Stage IV, V) | 7.7% | 1.5% | |
| Concurrent Drugs (+/− 90 days of initiating DOAC) | |||
| SSRI/SNRI | 33.7% | 29.1% | < 0.001 |
| Strong and moderate P-GP inhibitors | 18.3% | 18.5% | 0.63 |
| P-GP inducers | 18.5% | 16.5% | < 0.001 |
| Strong P-GP and CYP3A4 dual inhibitors | 22.7% | 20.8% | 0.002 |
| P-GP and CYP3A4 inducers | 18.5% | 16.5% | < 0.001 |
| ACE inhibitors | 67.4% | 64.3% | < 0.001 |
| Warfarin | 15.0% | 16.1% | 0.045 |
| Angiotensin receptor blockers | 40.0% | 36.7% | < 0.001 |
| Beta blockers | 88.1% | 86.5% | 0.015 |
| Calcium channel blockers | 64.5% | 59.4% | < 0.001 |
| Digoxin | 23.1% | 20.8% | < 0.001 |
| Proton pump inhibitors | 58.3% | 52.3% | < 0.001 |
| NSAIDs | 52.9% | 50.1% | < 0.001 |
| Antiplatelets | 30.2% | 24.3% | < 0.001 |
| Insulin | 14.3% | 10.8% | < 0.001 |
| Statins | 79.3% | 77.6% | 0.006 |
| Antiarrhythmics | 40.4% | 43.1% | < 0.001 |
| Estimated Glomerular Filtration rate (ml/min/1.73 m2) | < 0.001 | ||
| < 30 | 7.5% | 1.3% | |
| 30–60 | 61.1% | 35.2% | |
| 60–90 | 28.8% | 56.7% | |
| > =90 | 2.6% | 6.8% | |
| CCI(Charlson Comorbodity Index), mean (standard deviation) | 5.05(3.65) | 3.71(3.34) | < 0.001 |